Resource Logo
NLM AIDSLINE

Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C.




 

Scand J Infect Dis. 1999;31(2):115-8. Unique Identifier : AIDSLINE

A total of 172 Swedish patients treated with interferon-alpha for at least 24 weeks and followed-up > or =24 weeks after treatment was stopped were analysed for pre-treatment factors of importance for achieving a virological sustained response (SR). Furthermore, the predictive value for a virological SR of a positive or negative HCV RNA test at week 12 of treatment was evaluated. A low baseline viral load and genotype non-1b were pre-treatment factors indicating a favourable response. Thus, 44% (38/86) of patients with a low baseline viral load vs. only 16% (14/86) of those with a high viral load had a virological SR (p<0.0001). Of patients with a negative qualitative HCV RNA test after 12 weeks of interferon treatment, 46% (44/95) had virological SR, whereas only 5.9% (4/68) of those with a positive test had (p<0.0001). Prolonged ( > 6 months) treatment with interferon-alpha tended to increase the chance of virological SR (p<0.052).

CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL Adolescence Adult Age Factors Aged Alanine Transaminase/METABOLISM Female Genotype Hepatitis C-Like Viruses/GENETICS/*PHYSIOLOGY Hepatitis C, Chronic/*DRUG THERAPY Human Interferon Alfa, Recombinant/THERAPEUTIC USE Interferon-alpha/*THERAPEUTIC USE Liver/ENZYMOLOGY Male Middle Age RNA, Viral/BLOOD Sex Factors Treatment Outcome *Viral Load



 




Information in this article was accurate in December 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.